Dr Mike Thomas, Chief Medical Adviser to Asthma UK, said: 'We are very disappointed to hear that the National Institute for Health and Clinical Excellence (NICE) does not intend to approve the pioneering asthma treatment omalizumab (Xolair) for use in children aged 6-11...
(more...)